Thalidomide combined with ifosfamide significantly improves survival in patients with pulmonary metastatic osteosarcoma

Thalidomide + IFO notably improves PFS and OS in patients with pulmonary metastatic osteosarcoma, demonstrating superior safety compared with the IFO-ETOP regimen.

Authors

Institutions

Publication Details

Journal
American Journal of Cancer Research
Published
2025-01-01
DOI
https://doi.org/10.62347/aewt1662
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Thalidomide combined with ifosfamide significantly improves survival in patients with pulmonary metastatic osteosarcoma

Yuanxiang Liu
American Journal of Cancer Research
Sarcoma Diagnosis and Treatment
article

Thalidomide combined with ifosfamide significantly improves survival in patients with pulmonary metastatic osteosarcoma

Yuanxiang Liu
article en

Abstract

Thalidomide + IFO notably improves PFS and OS in patients with pulmonary metastatic osteosarcoma, demonstrating superior safety compared with the IFO-ETOP regimen.

American Journal of Cancer ResearchVol. 15(8)
Huazhong University of Science and Technology (CN)
Openalex Percentile: Top 64%
Sarcoma Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Thalidomide combined with ifosfamide significantly improves survival in patients with pulmonary metastatic osteosarcoma — Yuanxiang Liu · American Journal of Cancer Research (2025) | TGRS Research Map | TGRS